The mechanism of procyanidin B1 in the treatment of nonalcoholic fatty liver disease based on network pharmacology and molecular docking

Abstract

Non-alcoholic fatty liver disease (NAFLD), a chronic liver disorder closely associated with metabolic dysfunction, has become a significant global health challenge. In recent years, procyanidin B1 (PB1) has demonstrated potential advantages in the prevention and personalized treatment of NAFLD through multi-target and multi-pathway intervention strategies, exerting comprehensive regulatory and synergistic effects. However, its precise therapeutic mechanisms remain unclear. This study employs network pharmacology to identify key targets and potential pathways involved in the treatment of NAFLD with PB1. Additionally, molecular docking analysis is conducted to validate the reliability of these targets. The findings provide a theoretical foundation for the development of PB1 as a potential therapeutic agent for NAFLD, offering insights for future experimental and clinical research.

Keywords

Procyanidin B1 / non-alcoholic fatty liver disease / network pharmacology / molecular docking

Acknowledgments

This project is funded by Livelihood Plan Project of Department of Science and Technology of Liaoning Province (2023-MSLH-090). Department of Education of Liaoning Province (LJ212410163061).

References

[1] Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss[J]. BMC Endocr Disord, 2022, 22(1): 63.

[2] Slouha E, Biput SJ, Kalloo AE, et al. Non-alcoholic fatty liver disease and gallstones: a systematic review[J]. Cureus, 2023, 15(9): 45027.

[3] Thilakarathna WPDW, Rupasinghe HP V. Proanthocyanidins-based synbiotics as a novel strategy for nonalcoholic fatty liver disease (NAFLD) risk reduction[J]. Molecules, 2024, 29(3): 709.

[4] Rong L, Zou J, Ran W, et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)[J]. Front Endocrinol (Lausanne), 2023, 13: 1087260.

[5] Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non‐alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association[J]. Hepatology, 2012, 55(6): 2005-2023.

[6] Milić S, Lulić D, Štimac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations[J]. World J Gastroenterol, 2014, 20(28): 9330.

[7] Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression[J]. Cell Mol Life Sci, 2019, 76: 99-128.

[8] Liu W, Baker RD, Bhatia T, et al. Pathogenesis of nonalcoholic steatohepatitis[J]. Cell Mol Life Sci, 2016, 73: 1969-1987.

[9] Zhang J, Liang R, Wang L, et al. Effects and mechanisms of Danshen-Shanzha herb-pair for atherosclerosis treatment using network pharmacology and experimental pharmacology[J]. J Ethnopharmacol, 2019, 229: 104-114.

[10] Chen L, Cao Y, Zhang H, et al. Network pharmacology- based strategy for predicting active ingredients and potential targets of Yangxinshi tablet for treating heart failure[J]. J Ethnopharmacol, 2018, 219: 359-368.

[11] Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines[J]. J Cheminform, 2014, 6: 1-6.

[12] Xu J, Wang F, Guo J, et al. Pharmacological mechanisms underlying the neuroprotective effects of Alpinia oxyphylla Miq. on Alzheimer’s disease[J]. Int J Mol Sci, 2020, 21(6): 2071.

[13] Ding Z, Zhong R, Yang Y, et al. Systems pharmacology reveals the mechanism of activity of Ge-Gen-Qin-Lian decoction against LPS-induced acute lung injury: a novel strategy for exploring active components and effective mechanism of TCM formulae[J]. Pharmacol Res, 2020, 156: 104759.

[14] Li X, Liu Z, Liao J, et al. Network pharmacology approaches for research of Traditional Chinese Medicines[J]. Chin J Nat Med, 2023, 21(5): 323-332.

[15] Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome- wide experimental datasets[J]. Nucleic Acids Res, 2019, 47(D1): D607-D613.

[16] Huang C, Li R, Shi W, et al. Discovery of the anti-tumor mechanism of calycosin against colorectal cancer by using system pharmacology approach[J]. Med Sci Monit, 2019, 25: 5589.

[17] Szklarczyk D, Franceschini A, Wyder S, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life[J]. Nucleic Acids Res, 2015, 43(D1): D447-D452.

[18] Dichtel LE, Corey KE, Haines MS, et al. The GH/IGF- 1 axis is associated with intrahepatic lipid content and hepatocellular damage in overweight/obesity[J]. J Clin Endocrinol Metab, 2022, 107(9): e3624-e3632.

[19] Friedman SL, Neuschwander-Tetri BA, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies[J]. Nat Med, 2018, 24(7): 908-922.

[20] Watt MJ, Miotto PM, De Nardo W, et al. The liver as an endocrine organ—linking NAFLD and insulin resistance[J]. Endocr Rev, 2019, 40(5): 1367-1393.

[21] Gaul S, Leszczynska A, Alegre F, et al. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis[J]. J Hepatol, 2021, 74(1): 156-167.

[22] Kim KA, Tran NKS, Baek J, et al. Proanthocyanidins and phenolic compounds from the twigs of salix chaenomeloides and their anti-lipogenic effects on 3t3-l1 preadipocytes[J]. Nutrients, 2024, 16(7): 1036.

[23] Deng ZJ, Zhao JF, Huang F, et al. Protective effect of procyanidin B2 on acute liver injury induced by aflatoxin B1 in rats[J]. Biomed Environ Sci, 2020, 33(4): 238-247.

[24] Tie F, Wang J, Liang Y, et al. Proanthocyanidins ameliorated deficits of lipid metabolism in type 2 diabetes mellitus via inhibiting adipogenesis and improving mitochondrial function[J]. Int J Mol Sci, 2020, 21(6): 2029.

[25] Hopkins AL. Network pharmacology: the next paradigm in drug discovery[J]. Nat Chem Biol, 2008, 4(11): 682-690.

[26] Rogowicz-Frontczak A, Majchrzak A, Zozulińska-Ziółkiewicz D. Insulin resistance in endocrine disorders— treatment options[J]. Endokrynol Pol, 2017, 68(3): 334-351.

[27] Musso G, Gambino R, Cassader M, et al. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity[J]. Ann Med, 2011, 43(8): 617-649.

[28] Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites[J]. Hepatology, 2010, 52(2): 774-788.

[29] Bugianesi E, Gastaldelli A, Vanni E, et al. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms[J]. Diabetologia, 2005, 48: 634-642.

[30] Deng J. How to unleash mitochondrial apoptotic blockades to kill cancers[J]. Acta Pharm Sin B, 2017, 7(1): 18-26.

[31] Liu B, Deng X, Jiang Q, et al. Scoparone improves hepatic inflammation and autophagy in mice with nonalcoholic steatohepatitis by regulating the ROS/P38/Nrf2 axis and PI3K/AKT/mTOR pathway in macrophages[J]. Biomed Pharmacother, 2020, 125: 109895.

[32] Probst D, Reymond JL. Exploring DrugBank in virtual reality chemical space[J]. J Chem Inf Model, 2018, 58(9): 1731-1735.